Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus TETREX.
ACHROMYCIN vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic